Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.

Zheng J, Parizo JT, Spertus JA, Heidenreich PA, Sandhu AT

Open source

DOI
10.1001/jamainternmed.2022.5010
Published
2022 Dec 1
Container
JAMA internal medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamainternmed.2022.5010,
  title = {Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.},
  author = {Zheng J and Parizo JT and Spertus JA and Heidenreich PA and Sandhu AT},
  year = {2022},
  journal = {JAMA internal medicine},
  doi = {10.1001/jamainternmed.2022.5010},
  url = {https://doi.org/10.1001/jamainternmed.2022.5010}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
AU  - Zheng J
AU  - Parizo JT
AU  - Spertus JA
AU  - Heidenreich PA
AU  - Sandhu AT
PY  - 2022
JO  - JAMA internal medicine
DO  - 10.1001/jamainternmed.2022.5010
UR  - https://doi.org/10.1001/jamainternmed.2022.5010
ER  - 

APA

J, Z., JT, P., JA, S., PA, H., & AT, S. (2022). Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.. JAMA internal medicine. https://doi.org/10.1001/jamainternmed.2022.5010

Source records